Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis

Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis

Coronary heart disease (CHD) is a type of cardiovascular disease (CVD) caused by coronary atherosclerosis. It is a main cause of medical burden and cardiovascular related death. Zhishi Xiebai Guizhi Decoction (ZXGD) is a representative prescription of traditional Chinese medicine (TCM) in the treatm...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2024-01, Vol.103 (3), p.e36588-e36588
Hauptverfasser: Li, Ming, Song, Shengqiang, Rong, Yuanhang, Wu, Di, Yin, Yongtian
Format: Artikel
Sprache:eng
Schlagworte:
Cardiovascular Diseases
Cholesterol, LDL
Coronary Disease - drug therapy
Drugs, Chinese Herbal
Humans
Lipids
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e36588
container_issue 3
container_start_page e36588
container_title Medicine (Baltimore)
container_volume 103
creator Li, Ming
Song, Shengqiang
Rong, Yuanhang
Wu, Di
Yin, Yongtian
description Coronary heart disease (CHD) is a type of cardiovascular disease (CVD) caused by coronary atherosclerosis. It is a main cause of medical burden and cardiovascular related death. Zhishi Xiebai Guizhi Decoction (ZXGD) is a representative prescription of traditional Chinese medicine (TCM) in the treatment of CHD, but there is poor systemically evidence-based appraisal. To evaluate the efficacy and safety of ZXGD for CHD. Eight databases were retrieved for randomized controlled trials (RCTs). Data was extracted independently by 2 reviewers. The quality of the included studies was assessed by Cochrane Collaboration risk of bias tool. Clinical efficacy, blood lipid, vascular endothelial function, inflammatory factor and homocysteine (Hcy) were prespecified outcome measures. Twenty-four studies (2272 patients) were included. Meta-analysis showed that compared with conventional western medicine (WM) alone, ZXGD was associated with a greater symptom improvement rate with a relative risk (RR) of 1.21 [95% CI (1.16, 1.26), P 
doi_str_mv 10.1097/MD.0000000000036588
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2917553494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2917553494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-9a1ca5a6c8237c78593cea872e23597cfcfe3ac0fffee7603b2d30b7748715fe3</originalsourceid><addsrcrecordid>eNpdkE9LAzEQxYMotlY_gSA5etmaP5vNxluxWoUWLwriZc1mJzTS3dRkV6mf3pVWBecyDPPePOaH0CklY0qUvFhMx-SveCbyfA8NqeBZIlSW7qMhIUwkUsl0gI5ifCWEcsnSQzTgOUupUOkQvTwvXVw6_OSg1A7POvfZT1Mw3rTON9j6gI0PvtFhg5egQ4srF0FHuMQTHDexhVq3zuAA7w4-sG4qXEOrE93o1Sa6eIwOrF5FONn1EXq8uX64uk3m97O7q8k8MZyQNlGaGi10ZnLGpZG5UNyAziUDxoWSxhoLXBtirQWQGeElqzgppUxzSUW_G6Hz7d118G8dxLaoXTSwWukGfBcLpqgUgqcq7aV8KzXBxxjAFuvg6v7BgpLiG22xmBb_0faus11AV9ZQ_Xp-WPIvCEB04A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2917553494</pqid></control><display><type>article</type><title>Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Li, Ming ; Song, Shengqiang ; Rong, Yuanhang ; Wu, Di ; Yin, Yongtian</creator><creatorcontrib>Li, Ming ; Song, Shengqiang ; Rong, Yuanhang ; Wu, Di ; Yin, Yongtian</creatorcontrib><description><![CDATA[Coronary heart disease (CHD) is a type of cardiovascular disease (CVD) caused by coronary atherosclerosis. It is a main cause of medical burden and cardiovascular related death. Zhishi Xiebai Guizhi Decoction (ZXGD) is a representative prescription of traditional Chinese medicine (TCM) in the treatment of CHD, but there is poor systemically evidence-based appraisal. To evaluate the efficacy and safety of ZXGD for CHD. Eight databases were retrieved for randomized controlled trials (RCTs). Data was extracted independently by 2 reviewers. The quality of the included studies was assessed by Cochrane Collaboration risk of bias tool. Clinical efficacy, blood lipid, vascular endothelial function, inflammatory factor and homocysteine (Hcy) were prespecified outcome measures. Twenty-four studies (2272 patients) were included. Meta-analysis showed that compared with conventional western medicine (WM) alone, ZXGD was associated with a greater symptom improvement rate with a relative risk (RR) of 1.21 [95% CI (1.16, 1.26), P < .00001] and a greater electrocardiogram (ECG) improvement rate with a RR of 1.27 [95% CI (1.16, 1.40), P < .00001]. In terms of blood lipid, ZXGD reduced total cholesterol (TC) with a mean difference (MD) of -1.15 [95%CI (-1.75, -0.55), P = .0002] and triglyceride (TG) [MD = -0.72, 95%CI (-0.99, -0.45), P < .00001], reduced low-density lipoprotein cholesterol (LDL-C) [MD = -0.93, 95% CI (-1.17, -0.69), P < .00001], and increased high-density lipoprotein cholesterol (HDL-C) [MD = 0.31, 95%CI (0.20, 0.42), P < .00001]. In terms of vascular endothelial function, ZXGD decreased the level of endothelin-1 (ET-1) [MD = -7.81, 95%CI (-9.51, -6.10), P < .00001], and increased nitric oxide (NO) [MD = 8.90, 95%CI (7.86, 9.93), P < .00001]. ZXGD also reduced high-sensitivity C-reactive protein (hs-CRP) [MD = -1.73, 95% CI (-2.63, -0.83), P < .00001] and Hcy [MD = -2.03, 95%CI (-2.78, -1.28), P < .00001]. No significant differences were found in adverse event rate between the 2 groups with a RR of 0.77 [95% CI (0.44, 1.34), P = .36]. ZXGD is effective and safe in the treatment of CHD. However, more rigorous and high-quality RCTs are needed to verify the conclusion.]]></description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000036588</identifier><identifier>PMID: 38241594</identifier><language>eng</language><publisher>United States</publisher><subject>Cardiovascular Diseases ; Cholesterol, LDL ; Coronary Disease - drug therapy ; Drugs, Chinese Herbal ; Humans ; Lipids</subject><ispartof>Medicine (Baltimore), 2024-01, Vol.103 (3), p.e36588-e36588</ispartof><rights>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-9a1ca5a6c8237c78593cea872e23597cfcfe3ac0fffee7603b2d30b7748715fe3</cites><orcidid>0000-0001-9017-2057</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38241594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Ming</creatorcontrib><creatorcontrib>Song, Shengqiang</creatorcontrib><creatorcontrib>Rong, Yuanhang</creatorcontrib><creatorcontrib>Wu, Di</creatorcontrib><creatorcontrib>Yin, Yongtian</creatorcontrib><title>Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description><![CDATA[Coronary heart disease (CHD) is a type of cardiovascular disease (CVD) caused by coronary atherosclerosis. It is a main cause of medical burden and cardiovascular related death. Zhishi Xiebai Guizhi Decoction (ZXGD) is a representative prescription of traditional Chinese medicine (TCM) in the treatment of CHD, but there is poor systemically evidence-based appraisal. To evaluate the efficacy and safety of ZXGD for CHD. Eight databases were retrieved for randomized controlled trials (RCTs). Data was extracted independently by 2 reviewers. The quality of the included studies was assessed by Cochrane Collaboration risk of bias tool. Clinical efficacy, blood lipid, vascular endothelial function, inflammatory factor and homocysteine (Hcy) were prespecified outcome measures. Twenty-four studies (2272 patients) were included. Meta-analysis showed that compared with conventional western medicine (WM) alone, ZXGD was associated with a greater symptom improvement rate with a relative risk (RR) of 1.21 [95% CI (1.16, 1.26), P < .00001] and a greater electrocardiogram (ECG) improvement rate with a RR of 1.27 [95% CI (1.16, 1.40), P < .00001]. In terms of blood lipid, ZXGD reduced total cholesterol (TC) with a mean difference (MD) of -1.15 [95%CI (-1.75, -0.55), P = .0002] and triglyceride (TG) [MD = -0.72, 95%CI (-0.99, -0.45), P < .00001], reduced low-density lipoprotein cholesterol (LDL-C) [MD = -0.93, 95% CI (-1.17, -0.69), P < .00001], and increased high-density lipoprotein cholesterol (HDL-C) [MD = 0.31, 95%CI (0.20, 0.42), P < .00001]. In terms of vascular endothelial function, ZXGD decreased the level of endothelin-1 (ET-1) [MD = -7.81, 95%CI (-9.51, -6.10), P < .00001], and increased nitric oxide (NO) [MD = 8.90, 95%CI (7.86, 9.93), P < .00001]. ZXGD also reduced high-sensitivity C-reactive protein (hs-CRP) [MD = -1.73, 95% CI (-2.63, -0.83), P < .00001] and Hcy [MD = -2.03, 95%CI (-2.78, -1.28), P < .00001]. No significant differences were found in adverse event rate between the 2 groups with a RR of 0.77 [95% CI (0.44, 1.34), P = .36]. ZXGD is effective and safe in the treatment of CHD. However, more rigorous and high-quality RCTs are needed to verify the conclusion.]]></description><subject>Cardiovascular Diseases</subject><subject>Cholesterol, LDL</subject><subject>Coronary Disease - drug therapy</subject><subject>Drugs, Chinese Herbal</subject><subject>Humans</subject><subject>Lipids</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE9LAzEQxYMotlY_gSA5etmaP5vNxluxWoUWLwriZc1mJzTS3dRkV6mf3pVWBecyDPPePOaH0CklY0qUvFhMx-SveCbyfA8NqeBZIlSW7qMhIUwkUsl0gI5ifCWEcsnSQzTgOUupUOkQvTwvXVw6_OSg1A7POvfZT1Mw3rTON9j6gI0PvtFhg5egQ4srF0FHuMQTHDexhVq3zuAA7w4-sG4qXEOrE93o1Sa6eIwOrF5FONn1EXq8uX64uk3m97O7q8k8MZyQNlGaGi10ZnLGpZG5UNyAziUDxoWSxhoLXBtirQWQGeElqzgppUxzSUW_G6Hz7d118G8dxLaoXTSwWukGfBcLpqgUgqcq7aV8KzXBxxjAFuvg6v7BgpLiG22xmBb_0faus11AV9ZQ_Xp-WPIvCEB04A</recordid><startdate>20240119</startdate><enddate>20240119</enddate><creator>Li, Ming</creator><creator>Song, Shengqiang</creator><creator>Rong, Yuanhang</creator><creator>Wu, Di</creator><creator>Yin, Yongtian</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9017-2057</orcidid></search><sort><creationdate>20240119</creationdate><title>Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis</title><author>Li, Ming ; Song, Shengqiang ; Rong, Yuanhang ; Wu, Di ; Yin, Yongtian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-9a1ca5a6c8237c78593cea872e23597cfcfe3ac0fffee7603b2d30b7748715fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cardiovascular Diseases</topic><topic>Cholesterol, LDL</topic><topic>Coronary Disease - drug therapy</topic><topic>Drugs, Chinese Herbal</topic><topic>Humans</topic><topic>Lipids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Ming</creatorcontrib><creatorcontrib>Song, Shengqiang</creatorcontrib><creatorcontrib>Rong, Yuanhang</creatorcontrib><creatorcontrib>Wu, Di</creatorcontrib><creatorcontrib>Yin, Yongtian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Ming</au><au>Song, Shengqiang</au><au>Rong, Yuanhang</au><au>Wu, Di</au><au>Yin, Yongtian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2024-01-19</date><risdate>2024</risdate><volume>103</volume><issue>3</issue><spage>e36588</spage><epage>e36588</epage><pages>e36588-e36588</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract><![CDATA[Coronary heart disease (CHD) is a type of cardiovascular disease (CVD) caused by coronary atherosclerosis. It is a main cause of medical burden and cardiovascular related death. Zhishi Xiebai Guizhi Decoction (ZXGD) is a representative prescription of traditional Chinese medicine (TCM) in the treatment of CHD, but there is poor systemically evidence-based appraisal. To evaluate the efficacy and safety of ZXGD for CHD. Eight databases were retrieved for randomized controlled trials (RCTs). Data was extracted independently by 2 reviewers. The quality of the included studies was assessed by Cochrane Collaboration risk of bias tool. Clinical efficacy, blood lipid, vascular endothelial function, inflammatory factor and homocysteine (Hcy) were prespecified outcome measures. Twenty-four studies (2272 patients) were included. Meta-analysis showed that compared with conventional western medicine (WM) alone, ZXGD was associated with a greater symptom improvement rate with a relative risk (RR) of 1.21 [95% CI (1.16, 1.26), P < .00001] and a greater electrocardiogram (ECG) improvement rate with a RR of 1.27 [95% CI (1.16, 1.40), P < .00001]. In terms of blood lipid, ZXGD reduced total cholesterol (TC) with a mean difference (MD) of -1.15 [95%CI (-1.75, -0.55), P = .0002] and triglyceride (TG) [MD = -0.72, 95%CI (-0.99, -0.45), P < .00001], reduced low-density lipoprotein cholesterol (LDL-C) [MD = -0.93, 95% CI (-1.17, -0.69), P < .00001], and increased high-density lipoprotein cholesterol (HDL-C) [MD = 0.31, 95%CI (0.20, 0.42), P < .00001]. In terms of vascular endothelial function, ZXGD decreased the level of endothelin-1 (ET-1) [MD = -7.81, 95%CI (-9.51, -6.10), P < .00001], and increased nitric oxide (NO) [MD = 8.90, 95%CI (7.86, 9.93), P < .00001]. ZXGD also reduced high-sensitivity C-reactive protein (hs-CRP) [MD = -1.73, 95% CI (-2.63, -0.83), P < .00001] and Hcy [MD = -2.03, 95%CI (-2.78, -1.28), P < .00001]. No significant differences were found in adverse event rate between the 2 groups with a RR of 0.77 [95% CI (0.44, 1.34), P = .36]. ZXGD is effective and safe in the treatment of CHD. However, more rigorous and high-quality RCTs are needed to verify the conclusion.]]></abstract><cop>United States</cop><pmid>38241594</pmid><doi>10.1097/MD.0000000000036588</doi><orcidid>https://orcid.org/0000-0001-9017-2057</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2024-01, Vol.103 (3), p.e36588-e36588
issn 0025-7974
1536-5964
language eng
recordid cdi_proquest_miscellaneous_2917553494
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection
subjects Cardiovascular Diseases
Cholesterol, LDL
Coronary Disease - drug therapy
Drugs, Chinese Herbal
Humans
Lipids
title Zhishi Xiebai Guizhi Decoction for coronary heart disease: A systematic review and meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A56%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Zhishi%20Xiebai%20Guizhi%20Decoction%20for%20coronary%20heart%20disease:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Li,%20Ming&rft.date=2024-01-19&rft.volume=103&rft.issue=3&rft.spage=e36588&rft.epage=e36588&rft.pages=e36588-e36588&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000036588&rft_dat=%3Cproquest_cross%3E2917553494%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2917553494&rft_id=info:pmid/38241594&rfr_iscdi=true